The FTC issued an administrative complaint to block Omnicare’s bid for a hostile acquisition of its biggest and only U.S. rival, PharMerica. Omnicare and PharMerica are long-term care pharmacies, which work with institutional providers like skilled nursing facilities. The FTC believes that the merger would allow Omnicare to raise the price of drugs for Medicare Part D because the number of skilled nursing facilities receiving services from Omnicare would “dramatically increas[e],” thereby also increasing Omnicare’s bargaining power to raise the price of drugs to Part D health plans.
Featured News
Saudi Arabia Reviews Uber’s $14.8 Billion Delivery Hero Takeover
Sep 24, 2026 by
CPI
Pope Leo Warns of AI Threats, Calls for Stronger Global Oversight
Sep 24, 2026 by
CPI
Paramount-Warner Bros. Discovery Merger Settlement Faces Coalition Challenge
Sep 24, 2026 by
CPI
New York Grocery Plan Puts Predatory-Pricing Rules to the Test
Sep 24, 2026 by
CPI
Nvidia CEO Opposes Antitrust, Liability Carveouts for AI Firms
Sep 24, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – National Security
Sep 22, 2026 by
CPI
National Security in U.S. Antitrust Enforcement: Toward a More Disciplined Framework
Sep 22, 2026 by
Rod Rosenstein & Timothy Finley
The Department of War’s M&A Review Guidance: What Companies in the Defense Industry Need to Know
Sep 22, 2026 by
Eric Stocking & Paul Ney
National Security, Resilience and the Boundaries of Merger Control
Sep 22, 2026 by
Beatriz Marques
National Security and Competition: Building Resilient Telecommunications Networks
Sep 22, 2026 by
Roslyn Layton